- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05224778
DMCRN-02-001: Beoordeling van pediatrische eindpunten in DM1 (ASPIRE-DM1)
Beoordeling van pediatrische eindpunten in DM1 (ASPIRE-DM1)
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Ruby Langeslay
- Telefoonnummer: 804-828-8481
- E-mail: ruby.langeslay@vcuhealth.org
Studie Contact Back-up
- Naam: Jennifer Raymond
- Telefoonnummer: 804-828-6318
- E-mail: jennifer.raymond@vcuhealth.org
Studie Locaties
-
-
-
Milan, Italië, 20162
- Werving
- Centro Clinico NeMO
-
Contact:
- Michela Nani
- E-mail: michela.nani@centrocliniconemo.it
-
Contact:
- Luca Mauro
- E-mail: luca.mauro@centrocliniconemo.it
-
Hoofdonderzoeker:
- Valeria Sansone, MD
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California, Los Angeles
-
Contact:
- Merve Kaleli
- E-mail: MKaleli@mednet.ucla.edu
-
Hoofdonderzoeker:
- Perry Shieh, MD, PhD
-
Contact:
- Dennis Fernando
- Telefoonnummer: 310-825-3264
- E-mail: DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway, Kansas, Verenigde Staten, 66205
- Werving
- University of Kansas Medical Center
-
Hoofdonderzoeker:
- Jeffrey Statland, MD
-
Contact:
- Michaela Walker
- E-mail: mwalker20@kumc.edu
-
Contact:
- Cassidy Nelson
- E-mail: cnelson15@kumc.edu
-
-
New York
-
Rochester, New York, Verenigde Staten, 14642
- Werving
- University of Rochester Medical Center
-
Contact:
- Jim Hilbert
- E-mail: james_hilbert@urmc.rochester.edu
-
Contact:
- Jeanne Dekdebrun
- E-mail: jeanne_dekdebrun@urmc.rochester.edu
-
Hoofdonderzoeker:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23298
- Werving
- Virginia Commonwealth University
-
Contact:
- Shantel Kyles
- E-mail: shantel.brown@vcuhealth.org
-
Hoofdonderzoeker:
- Nicholas E. Johnson, MD
-
Contact:
- Jodie Howell
- E-mail: jodie.howell@vcuhealth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
30 children with CDM
Beschrijving
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
Tijdsspanne: Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dysarthria Assessment
Tijdsspanne: Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
Tijdsspanne: Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
Tijdsspanne: Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
Tijdsspanne: Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
Tijdsspanne: Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
Tijdsspanne: Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
Tijdsspanne: Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
Tijdsspanne: Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
Tijdsspanne: Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nicholas E. Johnson, MD, Virginia Commonwealth University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Spierziekten
- Neuromusculaire aandoeningen
- Genetische ziekten, aangeboren
- Neurodegeneratieve ziekten
- Heredodegeneratieve aandoeningen, zenuwstelsel
- Spieraandoeningen, atrofisch
- Spierdystrofieën
- Myotone aandoeningen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Myotone dystrofie
Andere studie-ID-nummers
- HM20023386
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .